20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
26 analysts have expressed a variety of opinions on ACADIA Pharmaceuticals (NASDAQ:ACAD) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 13 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 5 | 6 | 3 | 0 | 0 |
| 2M Ago | 3 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $33.2, a high estimate of $42.00, and a low estimate of $19.00. This current average represents a 9.34% decrease from the previous average price target of $36.62.
Decoding Analyst Ratings: A Detailed Look
The perception of ACADIA Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $37.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $32.00 | - |
| Tessa Romero | JP Morgan | Lowers | Overweight | $25.00 | $29.00 |
| Jeffrey Hung | Morgan Stanley | Lowers | Overweight | $30.00 | $40.00 |
| David Hoang | Citigroup | Lowers | Buy | $30.19 | $38.00 |
| Gregory Renza | RBC Capital | Lowers | Outperform | $30.00 | $35.00 |
| Uy Ear | Mizuho | Lowers | Neutral | $25.00 | $39.00 |
| Jason Butler | JMP Securities | Lowers | Outperform | $39.00 | $44.00 |
| Charles Duncan | Cantor Fitzgerald | Lowers | Overweight | $37.00 | $42.00 |
| Joel Beatty | Baird | Lowers | Outperform | $31.00 | $40.00 |
| Jay Olson | Oppenheimer | Lowers | Perform | $19.00 | $25.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Neutral | $30.00 | $33.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $33.00 | $40.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $33.00 | - |
| Ami Fadia | Needham | Lowers | Buy | $32.00 | $36.00 |
| Tessa Romero | JP Morgan | Lowers | Overweight | $29.00 | $32.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $33.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
| Gregory Renza | RBC Capital | Lowers | Outperform | $35.00 | $36.00 |
| Uy Ear | Mizuho | Lowers | Buy | $39.00 | $40.00 |
| Ami Fadia | Needham | Lowers | Buy | $36.00 | $37.00 |
| Jason Butler | JMP Securities | Maintains | Market Outperform | $42.00 | - |
| Jay Olson | Oppenheimer | Maintains | Perform | $25.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $42.00 | - |
| Joel Beatty | Baird | Announces | Outperform | $40.00 | - |
| Joseph Stringer | Needham | Announces | Buy | $37.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ACADIA Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of ACADIA Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ACADIA Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on ACADIA Pharmaceuticals analyst ratings.
About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
ACADIA Pharmaceuticals: Financial Performance Dissected
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 69.27% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ACADIA Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.82% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.63%, the company showcases effective utilization of assets.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!